NEW YORK (GenomeWeb News) – Vaccine developer Affiris will use Probiogen's Human Artificial Lymph Node Technology (HuALN) as an analytical tool to find targets for its Affitome vaccination project, Affiris said today.
Under the agreement, Affiris will evaluate the HuALN technology as a human organoid model to study drug-related effects in the context of the human immune system in order to select possible vaccine candidates that it aims to take into clinical trials. HuALN's method of harvesting cells after bioreactor operation allows for functional testing and analysis of surface markers by flow cytometry, the firms said.
Vienna, Austria-based Affiris is developing tailor-made peptide vaccines against Alzheimer's disease, atherosclerosis, Parkinson's disease, hypertension, and four other conditions. It currently has two potential products for Alzheimer's that have completed phase I clinical trials.
"We have been looking for a system like the Human Artificial Lymph Node for quite a long time and are excited by the possibilities the system offers to test our peptide vaccine candidates," Affiris CEO Walter Schmidt said in a statement.
Financial terms of the agreement were not released.